CompanyGraph
At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $39.21M, above the global median of $18.73M
- FinancialsAltman Z-Score 4.96: safe zone
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
0.24%Below 5Y avg (0.43%)
Annual Rate
CNY 0.02Paid annual
Payout Ratio
17.4%Sustainable
Last Ex-Dividend
Jun 26, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
4.18BCNY624.08M · vs all stocks (USD)
Trailing P/E
68.25xRevenue (TTM)
926.49MCNY138.25M · vs all stocks (USD)
Profit Margin
6.35%Beta
0.2020xvs all stocks
52-Week Change
-6.83%vs all stocks
Market Capitalization
4.18BCNY624.08M · vs all stocks (USD)
Enterprise Value
3.60BCNY537.25M · vs all stocks (USD)
Trailing P/E
68.25xForward P/E
24.82xPrice to Sales (TTM)
4.51xPrice to Book (MRQ)
2.25xEnterprise to Revenue
3.89xEnterprise to EBITDA
31.68xGross Margin
29.56%Profit Margin
6.35%Operating Margin
5.74%Return on Assets (TTM)
1.34%Return on Equity (TTM)
2.95%Revenue (TTM)
926.49MCNY138.25M · vs all stocks (USD)
Revenue per Share (TTM)
1.81CNYUpdated Sep 19, 2026Quarterly Revenue Growth
7.30%Gross Profit (TTM)
309.38MCNY46.17M · vs all stocks (USD)
EBITDA (TTM)
172.41MCNY25.73M · vs all stocks (USD)
Net Income (TTM)
58.84MCNY8.78M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
59.30%Operating Cash Flow (TTM)
326.43MCNY48.71M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
262.77MCNY39.21M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0200CNYUpdated Sep 19, 2026Trailing Annual Dividend Yield
0.24%vs all stocks
5-Year Average Dividend Yield
0.43%vs all stocks
Payout Ratio
17.36%Minority Interest (Equity)
22.79MCNYFY2025 · Dec 31, 2025Revenue
915.53MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
603.42MCNYFY2025 · Dec 31, 2025Gross Profit
312.12MCNYFY2025 · Dec 31, 2025Operating Income
125.93MCNY18.79M · vs all stocks (USD)
Pre-tax Income
65.03MCNYFY2025 · Dec 31, 2025Income Tax Expense
18.08MCNYFY2025 · Dec 31, 2025Net Income
46.96MCNYFY2025 · Dec 31, 2025EBIT
65.80MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
172.41MCNYFY2025 · Dec 31, 2025Research & Development
24.56MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
76.52MCNYFY2025 · Dec 31, 2025Other Operating Expenses
18.43MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
5.90MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
770.72KCNYFY2025 · Dec 31, 2025EPS (Basic)
0.0964CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.0964CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
510.45MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
510.45MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
46.96MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
2.25MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
8.51MCNYFY2025 · Dec 31, 2025Free Cash Flow
-9.77MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
524.49MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
46.96MCNYFY2025 · Dec 31, 2025Other Non-cash Items
4.55MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-86.74MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
43.74MCNYFY2025 · Dec 31, 2025Capital Expenditures
-18.28MCNYFY2025 · Dec 31, 2025Purchase of Investments
-20.00MCNYFY2025 · Dec 31, 2025Other Investing Activity
-18.87KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-38.30MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
16.00MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-23.90MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-7.02MCNYFY2025 · Dec 31, 2025Other Financing Charges
-928.89KCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-15.85MCNYFY2025 · Dec 31, 2025Shares Outstanding
510.66MSharesUpdated Sep 19, 2026Float Shares
189.17MSharesUpdated Sep 19, 2026% Held by Insiders
67.40%vs all stocks
% Held by Institutions
0.97%vs all stocks
Total Cash (MRQ)
634.61MCNY94.70M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.24CNYUpdated Sep 19, 2026Total Debt (MRQ)
31.80MCNY4.75M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0169xCurrent Ratio (MRQ)
2.88xBook Value per Share (MRQ)
3.65CNYUpdated Sep 19, 2026Total Assets
2.55BCNY380.14M · vs all stocks (USD)
Total Current Assets
1.33BCNYFY2025 · Dec 31, 2025Total Liabilities
692.03MCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.21BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
251.41MCNYFY2025 · Dec 31, 2025Total Current Liabilities
440.62MCNYFY2025 · Dec 31, 2025Cash
524.49MCNYFY2025 · Dec 31, 2025Cash Equivalents
153.00CNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
524.49MCNYFY2025 · Dec 31, 2025Accounts Receivable
301.93MCNYFY2025 · Dec 31, 2025Inventory
289.84MCNYFY2025 · Dec 31, 2025Accounts Payable
263.63MCNYFY2025 · Dec 31, 2025Short-term Debt
37.78MCNYFY2025 · Dec 31, 2025Other Current Liabilities
23.88MCNYFY2025 · Dec 31, 2025Long-term Debt
7.71MCNYFY2025 · Dec 31, 2025Common Stock (Book)
510.66MCNYFY2025 · Dec 31, 2025Retained Earnings
851.22MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.86BCNY276.87M · vs all stocks (USD)
52-Week Low
6.63CNYUpdated Sep 19, 202652-Week High
11.02CNYUpdated Sep 19, 202652-Week Change
-6.83%vs all stocks
Beta
0.2020xvs all stocks
50-Day MA
8.14CNYUpdated Sep 19, 2026200-Day MA
8.36CNYUpdated Sep 19, 2026Avg 10-Day Volume
5.38MSharesUpdated Sep 19, 2026Avg 30-Day Volume
10.23MSharesUpdated Sep 19, 2026Diluted EPS (TTM)
0.1200CNYUpdated Sep 19, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Financial Health
Altman Z-Score 4.96: safe zoneNotable
Altman Z-Score: 4.96
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $39.21M, above the global median of $18.73MNotable
Levered free cash flow (USD): 39,210,155.009Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
Tianjin Lisheng Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Sailun Biotech Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Aura Biosciences Inc.
Tier 1ProductionApproval-Gated PipelineRule
Guangdong Biolight Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
TTY Biopharm Company Limited
Tier 1ProductionApproval-Gated PipelineRule
Jianmin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Vishee Medical Technology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
IOL Chemicals and Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Hangzhou Minsheng Healthcare Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
CorMedix Inc.
Tier 1ProductionApproval-Gated PipelineRuleFlow